

Noemie Defourny

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4716500/noemie-defourny-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

432
citations

8
h-index

11
g-index

11
ext. papers

573
ext. citations

2.8
avg, IF

2.44
L-index

#	Paper	IF	Citations
10	Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. <i>Radiotherapy and Oncology</i> , 2014 , 112, 155-64	5.3	109
9	The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. <i>Radiotherapy and Oncology</i> , 2015 , 116, 38-44	5.3	93
8	Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey. <i>Radiotherapy and Oncology</i> , 2014 , 112, 178-86	5.3	63
7	The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. <i>Radiotherapy and Oncology</i> , 2015 , 116, 45-50	5.3	53
6	Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey. <i>Radiotherapy and Oncology</i> , 2014 , 112, 165-77	5.3	44
5	Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis. <i>Radiotherapy and Oncology</i> , 2016 , 121, 468-474	5.3	24
4	How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement. <i>Lancet Oncology</i> , 2020 , 21, e42-e54	21.7	19
3	National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project. <i>Radiotherapy and Oncology</i> , 2019 , 138, 187-194	5.3	17
2	Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data?. <i>Radiotherapy and Oncology</i> , 2019 , 141, 14-26	5.3	5
1	The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium. <i>Radiotherapy and Oncology</i> , 2020 , 145, 215-222	5.3	4